Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EBITDA (2022 - 2025)

Bioregenx's EBITDA history spans 4 years, with the latest figure at -$1.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$1.0 million for Q4 2025, up 94.47% from a year ago — trailing twelve months through Dec 2025 was -$1.5 million (up 93.29% YoY), and the annual figure for FY2025 was -$1.5 million, up 93.29%.
  • EBITDA for Q4 2025 was -$1.0 million at Bioregenx, down from -$73343.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $18209.0 in Q3 2022 to a low of -$18.4 million in Q4 2024.
  • The 4-year median for EBITDA is -$263301.5 (2023), against an average of -$1.8 million.
  • The sharpest move saw EBITDA crashed 13934.01% in 2023, then soared 94.47% in 2025.
  • Year by year, EBITDA stood at -$5535.0 in 2022, then plummeted by 4555.65% to -$257690.0 in 2023, then plummeted by 7039.04% to -$18.4 million in 2024, then soared by 94.47% to -$1.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.0 million, -$73343.0, and -$185542.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.